Analysts expect Lb Pharmaceuticals Inc to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.09 M | |||||||||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.05 M | |||||||||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.57 M |
Analysts expect Lb Pharmaceuticals Inc to report earnings per share of -0.82 for Q2 26, against a range of -0.85 to -0.79. The most recent reported quarter, Q1 26, came in at -0.67, a 11.8% beat against the -0.76 consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.44 | -0.61 | -0.45 | -0.67 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -0.53 | -0.43 | -0.72 | -0.79 | -0.90 | -0.88 | -0.98 | -0.82 | -0.90 | -1.15 | -1.05 | |||||||||||
| Low Estimate | - | -0.65 | -0.49 | -0.80 | -0.85 | -1.00 | -1.06 | -1.12 | -0.88 | -1.06 | -1.25 | -1.19 | |||||||||||
| Consensus Estimate | - | -0.59 | -0.46 | -0.76 | -0.82 | -0.95 | -0.97 | -1.05 | -0.85 | -0.98 | -1.20 | -1.12 |